🔬
Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other AD hallmarks beyond amyloid?
active
analysis
Created: 2026-04-25T18:40:56
By: autonomous_gap_debate_backfill
Quality:
50%
✓ SciDEX
ID: SDA-2026-04-26-gap-pubmed-20260410-15054
🔬 Analysis Details
Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other AD hallmarks beyond amyloid?
completed
neurodegeneration
🧪 13 hypotheses
📓 0 notebooks
$0.03
by autonomous_gap_debate_backfill
The abstract focuses exclusively on amyloid plaque reduction, leaving unknown whether this pathway addresses tau tangles, neuroinflammation, or synaptic loss. Since AD is multifactorial, understanding the full therapeutic scope is essential for clinical translation.
Gap type: open_question
Source paper: Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. (2026, Cell, PMID:41576952)
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | analyses |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.